|
Trendlines Tips | |
Israel in America
 By D. Todd Dollinger, Chairman and CEO of The Trendlines Group
I'm often in the States and it seems that I hear Hebrew everywhere. In a WalMart in Kansas, in a restaurant in Los Angeles, or in a clothing store in Baltimore. This is a Baltimore story - or an Israeli story.
Shopping at Brooks Brothers in Baltimore recently (shirts on sale, thank you very much), the kindly saleswoman with an unrecognizable accent suggested a shirt to me. I said "No, thanks." She smiled and moved on.
After a brief discussion, she told me that a few of the shirts that I wanted were sold out, but that she would be happy to order them for me. I told her that I live "out of town." She asked, "Where?" I replied: "Israel." And there it started. |
|
News from The Trendlines Group |
Announcing: The Maryland/Israel Trendlines Fund, L.P.
The Maryland/Israel Trendlines Fund provides investors with an ooportunity for substantial long-term capital appreciation through investment in early-stage Israeli companies in the life sciences, and agrotech/cleantech industries.  The Fund's General Partner, MIDC Corp. (a subsidiary of Maryland/Israel Development Center), and The Trendlines Group, combine a proven investment track record with tens of years of experiences in supporting young Israeli companies entering the U.S. and global markets. D. Todd Dollinger was quoted in an April Jerusalem Post article reporting on the the Fund that the MIDC "is a private-sector group that works to help bring cutting-edge technology to the U.S., helping them navigate unfamiliar and often intimidating territory."
Trendlines and the MIDC have been successfully working together for 15 years to promote business between Israeli and U.S. companies: Together, we've assisted hundreds of companies in reaching U.S. markets, supported Israeli companies' funding efforts, and facilitated the opening of more than 30 Israeli company offices in Maryland.
|
|
Trendlines in the Community |
Proud to Support Budding Israeli Entrepreneurs
Trendlines is proud to have sponsored the Grand Prize winning team of the "Doing Business" competition of Young Entrepreneurs Israel, a non-profit organization dedicated to exposing youth to the world of business and entrepreneurship. "Doing Business" is a competition in which high school students establish companies and develop new products, providing young people with the opportunity to develop personal skills (teamwork, leadership, presentation, etc.) while interacting with active companies in the Israeli market. The program, held this year on May 5, allows participants to experience each stage of a company's life cycle from initial capital  raising to formulating an initial concept for a product or service to appointing company officers to the development, production, marketing, advertising and sales of the product.
The winning group, Extaza Ltd., is comprised of fifteen 9th grade students from the Mevasseret Baruch religious girl's high school in Hadera. Avital Feldman, the president of the company, is the daughter of Aaron Feldman, CEO of CardioFlow, a Misgav Venture Accelerator portfolio company. Extaza's innovative product, the "Fun Cup," beat out 11 other finalist teams. "Fun Cup" offers "fun, safe and clean drinking suitable for children and adults." Congratulations, Extaza!
|
|
Trendlines in the News |
· The U.S. Road Show organized and led by The Trendlines Group in March was not only a huge success leading to five raises for our portfolio companies (see below in RAISES), but also appeared in various English and Hebrew news outlets including a feature in The Jerusalem Post. · D. Todd Dollinger, CEO and Chairman, The Trendlines Group, was quoted in an article in the May 2011 "Innovation" issue of CNBC Business, titled " Innovation Nation." · Steve Rhodes, CEO and Chairman, The Trendlines Group, was recently featured in Globes, Israel's business news wire, speaking in depth about the new Maryland/Israel Trendlines Fund (see above for details.) |
|
Upcoming Events |
ILSI-BioMed 2011 (May 23 - 25), Tel Aviv
Visit us at our Misgav Venture Accelerator's booth ( No. 39) at BioMed to meet with our portfolio companies. Three of our portfolio companies -- Immunovative, Stimatix GI, and Juvenis -- have been selected to present at various BioMed events. Refer to your BioMed schedule for more specific information, but please note the following times:
Stimatix GI presents at the David InterContinental, Hall A on Monday 13:30 - 13:50
Immunovative presents at the David InterContinental, Hall B on Monday 18:10 - 18:30
Juvenis presents at the David InterContinental, Hall D on Wednesday 11:55-12:00
Upcoming "Medinnovation" Course
The Entrepreneurship Center at Tel Aviv University in collaboration with The Trendlines Group's Misgav Venture Accelerator proudly presents:
Medinnovation : A Medical Technology Innovation Course
The purpose of this course is to help entrepreneurs better understand, and navigate, the steps involved in bringing a medical idea from concept to realization. The course will include lectures from leading industry professionals and will focus on the following topics:
· Overview of the medical device field
· Defining a need and validating your idea
· Writing a business plan
· Intellectual property aspects
· Regulation and clinical trials
· Reimbursement
· Project and budget planning
· Fund raising
· Legal aspects in forming a company and working with investors
Seminar for Electrical Product Manufacturers in Herzliya Trendines Group friend Rob Frier, president of MET Laboratories Inc. will present the following upcoming professional seminar in Herzliya, Israel.What: The seminar will include information and design tips to help electrical product manufacturers comply with regulatory and buyer requirements in North America and Europe. Topics to be covered include Product Safety, Electromagnetic Compatibility, NEBS, Wireless, ENERGY STAR, Metering and Smart Grid. When: May 24, 2011 Where: The Sharon Hotel, Herzliya Contact: Email Rob Frier for more information at rfrier@metlabs.com |
|
The Trendlines Portfolio |
ETView Announces Two Distribution Agreements
Tel Aviv Stock Exchange traded ETView Medical Ltd. (TASE: ETVW) has announced that it entered into distribution agreements with Stopler of Belgium and Korea's ChinooMTech. ETView's TVT™ combines high-flow ventilation airway management with continuous video monitoring to overcome current limitations and associated adverse surgical events during lung isolation surgeries.
Juvenis To Begin Clinical Trial
Juvenis, which is developing biomaterials for tissue augmentation and reconstruction, was featured recently both in Israel 21c and on the Ministry of Foreign Affairs web site. The company, which holds several patents, is aiming for European Union approval by 2013.
Vacciguard's Progress Noted by Investors and News OutletsVacciguard, which recently raised $1.4 million was featured recently in both Globes and Israel 21C. Vacciguard is developing effective, long lasting vaccines against some of the world's deadliest maladies, from cancer to CMV, and West Nile virus. Trendlines investors can access additional information on our portfolio companies through the password protected page on our website.
|
|
|
According to TechCrunch, the "Next 10 Years Will Be Great For Both Founders And VCs"
(Thanks to Sam Solomon for forwarding the following article.)
"Here is the important, and game-changing, point: in order to participate in the great wealth creation taking place in this and future technology cycles, you will have to be a founder, an early employee or a private investor. The so-called easy money will be earned before a company goes public. This is a radical shift from earlier technology cycles." Read the entire article.
2011 Med-Tech Mergers and Acquisitions: Deal Drivers for Middle Market Targets
Following a strong a 2010, consider this March 2011 blog post from Benning Associates on the prognosis for 2011 MedTech M & A: "While markets will continue to fluctuate, we can be confident that the sub-$100 million Med-Tech M&A market will continue to provide exit opportunities for smaller companies." Read the blog post. |
|
|
Trendlines U.S. Road Show Leads to Five Raises
Last month, 26 people from The Trendlines Group and 14 of its portfolio companies traveled coast to coast to four cities in five days: New York, Baltimore, Chicago and Los Angeles. At each stop, company representatives made five-minute presentations, conducted one-on-one "speed date" meetings, and networked at receptions with Trendlines' shareholders and other potential investors. The outcome? In addition to intense and productive meetings, Trendlines' shareholders and other investors agreed to invest more than $1 million in five of our portfolio companies.
Vacciguard Raises $1.4 Million for Developing Vaccine Technology
Campus Bio, the drug development division of Clal Biotech, is investing $1.4 million in Vacciguard, a Misgav Venture Accelerator company. Vacciguard's technology tool will be used for developing effective vaccines against a wide range of diseases from cancer to West Nile virus.
Stimatix Raises $1 Million to Proceed with Clinical Trials
Pontifax Fund, headed by Eli Hurvitz, has invested $1 million in Misgav Venture Accelerator portfolio company, Stimatix GI Medical Solutions Ltd. Founded in 2009, Stimatix GI is developing an artificial stomal cap which provides vastly improved bowel control for people with stoma. The company completed a preclinical trial in November, and will use the capital raised to finance a clinical trial of its product.
|
|
|
|
|
|
Staff News |
Signal Business Development welcomes Jen Maidenberg to the position of Senior Marketing Communications Consultant. Previously, Jen was the founder and CEO of Mindful Living NJ, an organization that promoted wellness-related businesses in the U.S. Jen's specialty was increasing her clients' profile and market reach through grassroots marketing techniques, social media, online community building, and targeted interaction with the local community and media. Prior to creating Mindful Living NJ, Jen was a creative marketing manager, writer and editor in the publishing industry.
|
|
|
